EASY-HIT: HIV full-replication technology for broad discovery of multiple classes of HIV inhibitors

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 12, 2010, Pages 5257-5268

  Kremb, Stephan ^a   Helfer, Markus ^a   Heller, Werner ^a   Hoffmann, Dieter ^b   Wolff, Horst ^a   Kleinschmidt, Andrea ^a   Cepok, Sabine ^c   Hemmer, Bernhard ^c   Durner, Jörg ^a   Brack Werner, Ruth ^a  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ARCTIUM LAPPA EXTRACT; DARUNAVIR; EFAVIRENZ; FLAVOPIRIDOL; NICOTIANA TABACUM EXTRACT; PLANT EXTRACT; PRUNELLA VULGARIS EXTRACT; RALTEGRAVIR; REV PROTEIN; SAQUINAVIR; STAVUDINE; UNCLASSIFIED DRUG; VIRUS PROTEIN; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARCTIUM LAPPA; ARTICLE; ASTERACEAE; CONTROLLED STUDY; DRUG SCREENING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; REPORTER GENE; TECHNOLOGY; TOBACCO; VIRUS INHIBITION; VIRUS REPLICATION;

ANTI-HIV AGENTS; CELL LINE; DRUG EVALUATION, PRECLINICAL; FLOW CYTOMETRY; HIV; HIV INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; MICROSCOPY, FLUORESCENCE; REPRODUCIBILITY OF RESULTS; VIRUS REPLICATION;

EID: 78649671314     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00515-10     Document Type: Article

References (61)

1. Adamson, C. S., and E. O. Freed. 2008. Recent progress in antiretrovirals-lessons from resistance. Drug Discov. Today 13:424-432.
2. Al-Jabri, A. A., M. D. Wigg, E. Elias, R. Lambkin, C. O. Mills, and J. S. Oxford. 2000. In vitro anti-HIV-1 virucidal activity of tyrosine-conjugated triand dihydroxy bile salt derivatives. J. Antimicrob. Chemother. 45:617-621.
3. Baba, M. 2004. Inhibitors of HIV-1 gene expression and transcription. Curr. Top. Med. Chem. 4:871-882.
4. Bar-Magen, T., R. D. Sloan, V. H. Faltenbacher, D. A. Donahue, B. D. Kuhl, M. Oliveira, H. Xu, and M. A. Wainberg. 2009. Comparative biochemical analysis of HIV-1 subtype B and C integrase enzymes. Retrovirology 6:103.
5. Barouch, D. H. 2008. Challenges in the development of an HIV-1 vaccine. Nature 455:613-619.
6. Blair, W. S., J. Isaacson, X. Li, J. Cao, Q. Peng, G. F. Kong, and A. K. Patick. 2005. A novel HIV-1 antiviral high throughput screening approach for the discovery of HIV-1 inhibitors. Antiviral Res. 65:107-116.
7. Cao, J., J. Isaacson, A. K. Patick, and W. S. Blair. 2005. High-throughput human immunodeficiency virus type 1 (HIV-1) full replication assay that includes HIV-1 Vif as an antiviral target. Antimicrob. Agents Chemother. 49:3833-3841.
8. Chiba-Mizutani, T., H. Miura, M. Matsuda, Z. Matsuda, Y. Yokomaku, K. Miyauchi, M. Nishizawa, N. Yamamoto, and W. Sugiura. 2007. Use of new T-cell-based cell lines expressing two luciferase reporters for accurately evaluating susceptibility to anti-human immunodeficiency virus type 1 drugs. J. Clin. Microbiol. 45:477-487.
9. Copeland, K. F. 2005. Modulation of HIV-1 transcription by cytokines and chemokines. Mini Rev. Med. Chem. 5:1093-1101.
10. Cos, P., L. Maes, D. Vanden Berghe, N. Hermans, L. Pieters, and A. Vlietinck. 2004. Plant substances as anti-HIV agents selected according to their putative mechanism of action. J. Nat. Prod. 67:284-293.
11. Daelemans, D., C. Pannecouque, G. N. Pavlakis, O. Tabarrini, and E. De Clercq. 2005. A novel and efficient approach to discriminate between preand post-transcription HIV inhibitors. Mol. Pharmacol. 67:1574-1580.
12. De Clercq, E. 2007. The design of drugs for HIV and HCV. Nat. Rev. Drug Discov. 6:1001-1018.
13. De Clercq, E. 2009. Looking back in 2009 at the dawning of antiviral therapy now 50 years ago an historical perspective. Adv. Virus Res. 73:1-53.
14. Donahue, D. A., R. D. Sloan, B. D. Kuhl, T. Bar-Magen, S. M. Schader, and M. A. Wainberg. 2010. Stage-dependent inhibition of HIV-1 replication by antiretroviral drugs in cell culture. Antimicrob. Agents Chemother. 54:1047-1054.
15. Dorsky, D. I., M. Wells, and R. D. Harrington. 1996. Detection of HIV-1 infection with a green fluorescent protein reporter system. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 13:308-313.
16. Eli Lilly and Company and the National Institutes of Health Chemical Genomics Center. 2008. Assay guidance manual, version 5.0. National Institutes of Health Chemical Genomics Center, Bethesda, MD. http://www.ncgc.nih.gov/ guidance/manual-toc.html.
17. Felber, B. K., and G. N. Pavlakis. 1988. A quantitative bioassay for HIV-1 based on trans-activation. Science 239:184-187.
18. Garcia, J. M., A. Gao, P. L. He, J. Choi, W. Tang, R. Bruzzone, O. Schwartz, H. Naya, F. J. Nan, J. Li, R. Altmeyer, and J. P. Zuo. 2009. High-throughput screening using pseudotyped lentiviral particles: a strategy for the identification of HIV-1 inhibitors in a cell-based assay. Antiviral Res. 81:239-247.
19. Gervaix, A., D. West, L. M. Leoni, D. D. Richman, F. Wong-Staal, and J. Corbeil. 1997. A new reporter cell line to monitor HIV infection and drug susceptibility in vitro. Proc. Natl. Acad. Sci. U. S. A. 94:4653-4658.
20. Geuenich, S., C. Goffinet, S. Venzke, S. Nolkemper, I. Baumann, P. Plinkert, J. Reichling, and O. T. Keppler. 2008. Aqueous extracts from peppermint, sage and lemon balm leaves display potent anti-HIV-1 activity by increasing the virion density. Retrovirology 5:27.
21. Greene, W. C., Z. Debyser, Y. Ikeda, E. O. Freed, E. Stephens, W. Yonemoto, R. W. Buckheit, J. A. Este, and T. Cihlar. 2008. Novel targets for HIV therapy. Antiviral Res. 80:251-265.
22. Hazen, R. J., R. J. Harvey, M. H. St Clair, R. G. Ferris, G. A. Freeman, J. H. Tidwell, L. T. Schaller, J. R. Cowan, S. A. Short, K. R. Romines, J. H. Chan, and L. R. Boone. 2005. Anti-human immunodeficiency virus type 1 activity of the nonnucleoside reverse transcriptase inhibitor GW678248 in combination with other antiretrovirals against clinical isolate viruses and in vitro selection for resistance. Antimicrob. Agents Chemother. 49:4465-4473.
23. Heredia, A., C. Davis, D. Bamba, N. Le, M. Y. Gwarzo, M. Sadowska, R. C. Gallo, and R. R. Redfield. 2005. Indirubin-3′-monoxime, a derivative of a Chinese antileukemia medicine, inhibits P-TEFb function and HIV-1 replication. AIDS 19:2087-2095.
24. Hoffmann, D., J. Seebach, A. Cosma, F. D. Goebel, K. Strimmer, H. M. Schatzl, and V. Erfle. 2008. Therapeutic vaccination reduces HIV sequence variability. FASEB J. 22:437-444. (Pubitemid 351225580)
25. Hubner, W., P. Chen, A. Del Portillo, Y. Liu, R. E. Gordon, and B. K. Chen. 2007. Sequence of human immunodeficiency virus type 1 (HIV-1) Gag localization and oligomerization monitored with live confocal imaging of a replication-competent, fluorescently tagged HIV-1. J. Virol. 81:12596-12607.
26. Jones, J., J. Rodgers, M. Heil, J. May, L. White, J. A. Maddry, T. M. Fletcher III, G. M. Shaw, J. L. Hartman IV, and O. Kutsch. 2007. High throughput drug screening for human immunodeficiency virus type 1 reactivating compounds. Assay Drug Dev. Technol. 5:181-189.
27. Ketas, T. J., P. J. Klasse, C. Spenlehauer, M. Nesin, I. Frank, M. Pope, J. M. Strizki, G. R. Reyes, B. M. Baroudy, and J. P. Moore. 2003. Entry inhibitors SCH-C, RANTES, and T-20 block HIV type 1 replication in multiple cell types. AIDS Res. Hum. Retroviruses 19:177-186.
28. Kimpton, J., and M. Emerman. 1992. Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene. J. Virol. 66:2232-2239.
29. Koh, Y., H. Nakata, K. Maeda, H. Ogata, G. Bilcer, T. Devasamudram, J. F. Kincaid, P. Boross, Y. F. Wang, Y. Tie, P. Volarath, L. Gaddis, R. W. Harrison, I. T. Weber, A. K. Ghosh, and H. Mitsuya. 2003. Novel bis- tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. Antimicrob. Agents Chemother. 47:3123-3129.
30. Lam, K. S. 2007. New aspects of natural products in drug discovery. Trends Microbiol. 15:279-289. (Pubitemid 46856162)
31. Little, S. J., S. Holte, J. P. Routy, E. S. Daar, M. Markowitz, A. C. Collier, R. A. Koup, J. W. Mellors, E. Connick, B. Conway, M. Kilby, L. Wang, J. M. Whitcomb, N. S. Hellmann, and D. D. Richman. 2002. Antiretroviral-drug resistance among patients recently infected with HIV. N. Engl. J. Med. 347:385-394.
32. Liu, S., S. Jiang, Z. Wu, L. Lv, J. Zhang, Z. Zhu, and S. Wu. 2002. Identification of inhibitors of the HIV-1 gp41 six-helix bundle formation from extracts of Chinese medicinal herbs Prunella vulgaris and Rhizoma cibotte. Life Sci. 71:1779-1791.
33. Maddon, P. J., D. R. Littman, M. Godfrey, D. E. Maddon, L. Chess, and R. Axel. 1985. The isolation and nucleotide sequence of a cDNA encoding the T cell surface protein T4: a new member of the immunoglobulin gene family. Cell 42:93-104.
34. McMahon, M. A., L. Shen, and R. F. Siliciano. 2009. New approaches for quantitating the inhibition of HIV-1 replication by antiviral drugs in vitro and in vivo. Curr. Opin. Infect. Dis. 22:574-582.
35. Menendez-Arias, L. 2002. Targeting HIV: antiretroviral therapy and development of drug resistance. Trends Pharmacol. Sci. 23:381-388.
36. Montefiori, D. C. 2009. Measuring HIV neutralization in a luciferase reporter gene assay. Methods Mol. Biol. 485:395-405.
37. Mori, T., B. R. O'Keefe, R. C. Sowder II, S. Bringans, R. Gardella, S. Berg, P. Cochran, J. A. Turpin, R. W. Buckheit, Jr., J. B. McMahon, and M. R. Boyd. 2005. Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp. J. Biol. Chem. 280:9345-9353.
38. Mosmann, T. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65:55-63.
39. Muller, B., J. Daecke, O. T. Fackler, M. T. Dittmar, H. Zentgraf, and H. G. Krausslich. 2004. Construction and characterization of a fluorescently labeled infectious human immunodeficiency virus type 1 derivative. J. Virol. 78:10803-10813.
40. Nakata, H., M. Amano, Y. Koh, E. Kodama, G. Yang, C. M. Bailey, S. Kohgo, H. Hayakawa, M. Matsuoka, K. S. Anderson, Y. C. Cheng, and H. Mitsuya. 2007. Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4′-ethynyl-2-fluoro-2′- deoxyadenosine. Antimicrob. Agents Chemother. 51:2701-2708.
41. Ochsenbauer-Jambor, C., J. Jones, M. Heil, K. P. Zammit, and O. Kutsch. 2006. T-cell line for HIV drug screening using EGFP as a quantitative marker of HIV-1 replication. Biotechniques 40:91-100.
42. Pal Singh, I. P., S. B. Bharate, and K. K. Bhutani. 2005. Anti-HIV natural products. Curr. Sci. 89:269-290.
43. Pauwels, R. 2006. Aspects of successful drug discovery and development. Antiviral Res. 71:77-89. (Pubitemid 44223771)
44. Peden, K., M. Emerman, and L. Montagnier. 1991. Changes in growth properties on passage in tissue culture of viruses derived from infectious molecular clones of HIV-1LAI, HIV-1MAL, and HIV-1ELI. Virology 185:661-672.
45. Reinke, R. A., D. J. Lee, B. R. McDougall, P. J. King, J. Victoria, Y. Mao, X. Lei, M. G. Reinecke, and W. E. Robinson, Jr. 2004. L-chicoric acid inhibits human immunodeficiency virus type 1 integration in vivo and is a noncompetitive but reversible inhibitor of HIV-1 integrase in vitro. Virology 326:203-219.
46. Richman, D. D., D. M. Margolis, M. Delaney, W. C. Greene, D. Hazuda, and R. J. Pomerantz. 2009. The challenge of finding a cure for HIV infection. Science 323:1304-1307.
47. Rishton, G. M. 2008. Natural products as a robust source of new drugs and drug leads: past successes and present day issues. Am. J. Cardiol. 101:43D-49D.
48. Rocancourt, D., C. Bonnerot, H. Jouin, M. Emerman, and J. F. Nicolas. 1990. Activation of a beta-galactosidase recombinant provirus: application to titration of human immunodeficiency virus (HIV) and HIV-infected cells. J. Virol. 64:2660-2668.
49. Rothenaigner, I., S. Kramer, M. Ziegler, H. Wolff, A. Kleinschmidt, and R. Brack-Werner. 2007. Long-term HIV-1 infection of neural progenitor populations. AIDS 21:2271-2281.
50. Simon, V., D. D. Ho, and Q. Abdool Karim. 2006. HIV/AIDS epidemiology, pathogenesis, prevention, and treatment. Lancet 368:489-504.
51. Svarovskaia, E. S., R. Barr, X. Zhang, G. C. Pais, C. Marchand, Y. Pommier, T. R. Burke, Jr., and V. K. Pathak. 2004. Azido-containing diketo acid derivatives inhibit human immunodeficiency virus type 1 integrase in vivo and influence the frequency of deletions at two-long-terminal-repeat-circle junctions. J. Virol. 78:3210-3222.
52. UNAIDS. 2008. 2008 Report on the global HIV/AIDS epidemic. UNAIDS/08.27E /JC1511E. Joint United Nations Programme on HIV/AIDS, Geneva, Switzerland.
53. Vodicka, M. A., W. C. Goh, L. I. Wu, M. E. Rogel, S. R. Bartz, V. L. Schweickart, C. J. Raport, and M. Emerman. 1997. Indicator cell lines for detection of primary strains of human and simian immunodeficiency viruses. Virology 233:193-198.
54. Wachinger, M., A. Kleinschmidt, D. Winder, N. von Pechmann, A. Ludvigsen, M. Neumann, R. Holle, B. Salmons, V. Erfle, and R. Brack-Werner. 1998. Antimicrobial peptides melittin and cecropin inhibit replication of human immunodeficiency virus 1 by suppressing viral gene expression. J. Gen. Virol. 79:731-740.
55. Wei, X., J. M. Decker, H. Liu, Z. Zhang, R. B. Arani, J. M. Kilby, M. S. Saag, X. Wu, G. M. Shaw, and J. C. Kappes. 2002. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46:1896-1905.
56. Westby, M., G. R. Nakayama, S. L. Butler, and W. S. Blair. 2005. Cell-based and biochemical screening approaches for the discovery of novel HIV-1 inhibitors. Antiviral Res. 67:121-140.
57. Wolff, H., R. Brack-Werner, M. Neumann, T. Werner, and R. Schneider. 2003. Integrated functional and bioinformatics approach for the identification and experimental verification of RNA signals: application to HIV-1 INS. Nucleic Acids Res. 31:2839-2851. (Pubitemid 37442128)
58. Wolff, H., K. Hadian, M. Ziegler, C. Weierich, S. Kramer-Hammerle, A. Kleinschmidt, V. Erfle, and R. Brack-Werner. 2006. Analysis of the influence of subcellular localization of the HIV Rev protein on Rev-dependent gene expression by multi-fluorescence live-cell imaging. Exp. Cell Res. 312:443-456.
59. Wu, Y., M. H. Beddall, and J. W. Marsh. 2007. Rev-dependent indicator T cell line. Curr. HIV Res. 5:394-402.
60. Yasuhara-Bell, J., and Y. Lu. 2010. Marine compounds and their antiviral activities. Antiviral Res. 86:231-240.
61. Zhang, J. H., T. D. Chung, and K. R. Oldenburg. 1999. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 4:67-73.